Canada Approves Generic Ozempic Alternative as Cost Questions Grow
Latest news on WhatsApp أجدد الأخبار على واتساب
Health Canada has approved the first generic semaglutide injection in the country, making Canada the first G7 nation to authorize a generic version of the drug widely known through the brand name Ozempic.
The product, submitted by Dr. Reddy’s Laboratories, was approved after Health Canada reviewed evidence related to safety, efficacy, and quality. The department said the injection is a generic version of Ozempic and is indicated for once-weekly treatment of adults with Type 2 diabetes to help manage blood sugar levels.
The decision is significant because semaglutide-based medicines have become some of the most closely watched drugs in the world, driven by high demand, cost pressures, and growing competition in the GLP-1 market.
Health Canada said it is currently reviewing eight additional submissions for generic semaglutide from different companies, with more regulatory decisions expected in the coming weeks and months.
The approval does not automatically mean an immediate or equal price drop for every patient. Final costs will depend on pharmacy pricing, insurance coverage, and public or private drug plans. Still, Health Canada noted that many generic medications in Canada are significantly cheaper than brand-name versions, which could create savings for patients and the health-care system if more competitors enter the market.
For Canadians living with Type 2 diabetes, the decision may become more than a regulatory milestone. It could help expand access to a treatment that has been widely discussed but often expensive or difficult to obtain.
The next questions are when the generic product will become available in pharmacies, how it will be priced, and whether insurers and drug plans will treat it as a lower-cost alternative for eligible patients.
